Loading organizations...
§ Private Profile · La Jolla, CA, USA
Resilience is a technology company.
Resilience operates as a biomanufacturing contract development and manufacturing organization, offering end-to-end solutions for complex medicines. The company specializes in developing and producing biologics, cell therapies, and gene therapies. It deploys advanced technologies across its network of facilities, providing scalable solutions for drug substance and drug product manufacturing, including fill/finish operations, device assembly, and packaging, to streamline the path from concept to commercialization.
The company was founded in 2020 by Robert Nelsen, co-founder and managing director of ARCH Venture Partners, with 8VC also participating as a co-founder. Nelsen initiated Resilience based on a critical insight into the fragility of biopharmaceutical supply chains and the growing demand for complex medicines. His vision was to establish a resilient manufacturing infrastructure capable of meeting future therapeutic needs and mitigating potential disruptions.
Resilience serves biopharmaceutical partners aiming to efficiently develop and deliver novel therapies to patients. Its mission is to transform the manufacturing landscape, ensuring medicines can be produced rapidly, safely, and sustainably at scale. The company strives to expand global access to advanced therapeutics by building a robust and reliable biomanufacturing ecosystem that fosters innovation and protects against supply chain vulnerabilities.
Resilience has raised $1.0B across 6 funding rounds.
Resilience has raised $1.0B in total across 6 funding rounds.
Resilience (National Resilience, Inc.) is a technology-focused biomanufacturing company and contract development and manufacturing organization (CDMO) dedicated to broadening access to complex medicines like biologics, vaccines, cell and gene therapies, and nucleic acids.[2][3][6] It builds a sustainable network of high-tech, end-to-end manufacturing facilities across North America (and expanding internationally) to produce treatments quickly, safely, and at scale, while protecting biopharmaceutical supply chains from disruptions.[2][4][6] Serving biotech firms of all sizes—from small innovators to large players—Resilience solves critical bottlenecks in biomanufacturing by offering flexible, adaptive facilities with regulatory expertise, advanced AI-driven platforms, and capacity that scales with client needs.[3][5][6] The company has shown strong growth momentum, including network expansions adding hundreds of jobs (e.g., in Cincinnati), recognition on BioSpace's 2025 Best Places to Work list, and backing from top VCs like ARCH Venture Partners and 8VC.[3][4][5]
Founded in 2020 amid the COVID-19 pandemic, Resilience emerged to address gaps in biomanufacturing capacity exposed by the global health crisis, with a mission to advance manufacturing technologies and redefine partnerships between CDMOs and innovators.[2][5][6] The founding executive team comprises industry veterans, supported by prominent VC firms ARCH Venture Partners and 8VC, enabling rapid scaling through strategic acquisitions of manufacturing and development facilities across North America.[4][5] Key early traction came from upgrading digital, quality, and capacity at these sites, instantly providing clients access to high-demand modalities and establishing Resilience as a leader in under four years.[5]
Resilience rides the wave of explosive growth in advanced therapies—cell/gene therapies, nucleic acids—where scientific breakthroughs outpace manufacturing capabilities, exacerbated by supply chain vulnerabilities revealed during pandemics.[2][6] Its timing is ideal post-2020, capitalizing on market forces like regulatory pressures for resilient biopharma supply chains, rising demand for scalable production, and investor focus on life sciences infrastructure.[4][5] By influencing the ecosystem through tech upgrades, international expansion, and VC-backed innovation, Resilience enables faster patient access to therapies, reduces disruption risks, and sets a new standard for CDMOs as strategic partners rather than mere service providers.[3][5][6]
Resilience is poised for accelerated growth through further facility expansions, international scaling, and deployment of AI/next-gen platforms to handle surging demand for complex modalities.[3][5][6] Trends like AI-driven biomanufacturing, personalized medicine, and global supply chain fortification will shape its trajectory, potentially amplifying its influence as a go-to CDMO for disruptive biotechs. As it evolves from rapid builder to ecosystem shaper, Resilience exemplifies how technology can future-proof essential medicines, turning vulnerability into scalable strength.
Resilience has raised $1.0B across 6 funding rounds. Most recently, it raised $25.0M Series U in May 2024.
Resilience has raised $1.0B in total across 6 funding rounds.
Resilience's investors include Picus Capital, Red River West, Heartcore Capital, HV Capital, HV Holtzbrinck Ventures, White Star Capital, Robert Gentz, Rubin Ritter, Cathay Innovation, Seaya Ventures, Singular, Intact Insurance Specialty Solutions.